Showing results (21-30 of 367) with videos related to
Sort By:
Pageof 37
Journal of Clinical Medicine|September 23, 2022
Human Primary Odontoblast-like Cell Cultures-A Focused Review Regarding Cell CharacterizationChristian Klein, Christian Meller, Edgar SchäferExpert Opinion on Biological Therapy|September 16, 2020
Anti-CD20 treatment for B-cell malignancies: current status and future directionsChristian Klein, Candice Jamois, Tina NielsenOncoimmunology|September 14, 2016
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumorsMarina Bacac, Christian Klein, Pablo UmanaMabs|September 7, 2021
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteinsMarlena Surowka, Wolfgang Schaefer, Christian KleinPhysical Review Letters|April 3, 2012
Interplay between nonequilibrium and equilibrium spin torque using synthetic ferrimagnetsChristian Klein, Cyril Petitjean, Xavier WaintalFoot & Ankle International|January 30, 2009
Radiographic evaluation for AVN following distal metatarsal Stoffella bunion osteotomyChristian Klein, Alexander Zembsch, Ulrich DornJournal of Immunology (Baltimore, Md. : 1950)|May 6, 2014
KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicityGrzegorz Terszowski, Christian Klein, Martin SternProceedings. Mathematical, Physical, and Engineering Sciences|December 9, 2014
Numerical study of fractional nonlinear Schrödinger equationsChristian Klein, Christof Sparber, Peter MarkowichOncology Research and Treatment|April 17, 2015
Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibodyValentin Goede, Christian Klein, Stephan StilgenbauerMabs|February 2, 2023
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapyChristina Claus, Claudia Ferrara-Koller, Christian KleinPageof 37